Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
-
REGULATORY PAFSC’s Second Committee Backs Approval of Novartis’s Secukinumab
December 1, 2014
-
BUSINESS EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
-
INTERVIEW Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.
November 28, 2014
-
ACADEMIA Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official
November 27, 2014
-
BUSINESS Kaken Banking on Clenafin to Boost Dermatology Biz
November 27, 2014
-
REGULATORY Debates on Yearly NHI Price Cuts Put on Hold as Attention Turns to Election
November 26, 2014
-
REGULATORY PAFSC First Committee Backs Approval of Takeda’s Vonoprazan
November 25, 2014
-
ORGANIZATION JPMA President Opposes Annual NHI Price Revision
November 21, 2014
-
REGULATORY Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
-
REGULATORY 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
-
REGULATORY Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
-
REGULATORY PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations
November 17, 2014
-
BUSINESS Combined Half-Year Sales of Major Japanese Drug Makers Up 2.8% Thanks to Overseas Sales
November 14, 2014
-
REGULATORY New Japan NIH Head Asks Pharma Industry to Suggest Ideas for Benefit of Japanese People
November 13, 2014
-
BUSINESS Generic Makers Back on Growth Track in First Half of FY2014
November 12, 2014
-
BUSINESS Kowa Looks to Triple Eye Drug Business with Glanatec
November 11, 2014
-
BUSINESS Feburic Grabs Top Slot for GP Market in September “Mind Share” Ranking
November 10, 2014
-
BUSINESS Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market
November 10, 2014
-
BUSINESS Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales
November 7, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…